ALTASCIENCES
9.12.2021 17:02:06 CET | Business Wire | Press release
Altasciences is pleased to have been chosen by XORTX Therapeutics, Inc. to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19. XORTX’s novel, proprietary formulations of xanthine oxidase inhibitors are aimed at reducing uric acid levels in order to slow the progression of the genetic disorder ADPKD, and protect against acute kidney injury following COVID-19 infection.
The first of several clinical trials to characterize XORTX’s novel, proprietary formulations of xanthine oxidase inhibitors, its purpose is to determine whether the increased bioavailability of oxypurinol demonstrated for this formulation in preclinical studies will be replicated in humans.
Dr. Allen Davidoff, President and CEO stated, “XORTX is pleased to be starting work with Altasciences as we initiate the characterization of our novel, proprietary formulations of xanthine oxidase inhibitors. This study marks the first of several clinical trials planned for the next year and an exciting opportunity to advance our kidney disease programs through preliminary characterization, followed by late stage registration trials. ”
“With a pressing need for better therapeutic options and a global prevalence of kidney disease, we are proud to partner with XORTX for such an important study. We look forward to supporting this innovative company in their goal of bringing a valuable new treatment to the next stage, and getting better drugs to the people who need them, faster, ” stated Ingrid Holmes, Vice President, Global Clinical Operations at Altasciences.
Altasciences offers a seamless drug development solution that allows sponsors to work with a single, integrated CRO/CDMO in support of early-phase research, from lead candidate selection to preclinical testing to clinical proof of concept in the most time- and cost-efficient way possible.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005134/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC and Xsolis’ Strategic Partnership to Tackle Inefficiencies in Healthcare Decision-Making with AI2.6.2026 14:38:00 CEST | Press release
Collaboration will accelerate the evolution of Xsolis’ Dragonfly platform, improving how healthcare providers and payers make faster, more aligned care decisions HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602462348/en/ HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. Across healthcare systems, determining whether a treatment is medically necessary, what level of care a patient requires, and whether that care will be approved remains a slow, manua
Perpetuals Reports $4.5 Billion in UpsideOnly Volume and Signs Exchange Agreement With Datavault AI for Tokenized Commodities2.6.2026 14:00:00 CEST | Press release
UpsideOnly draws more than 30,000 active users from 185 countries in its first two weeksPerpetuals signs exchange agreement with Datavault AI, bringing tokenized gold, copper, geothermal energy, and critical minerals to 24/7 regulated global trading Perpetuals.com Ltd (Nasdaq: PDC) today reported strong early results for its breakout UpsideOnly trading and market prediction platform and announced an agreement with Datavault AI Inc. (Nasdaq: DVLT) to list tokenized real-world commodity assets on the Perpetuals platform. In its first two weeks, traders flocked to the UpsideOnly platform, attracting more than 30,000 active users, generating $4.5 billion in cumulative platform volume across 186,000 fills and 25 instruments. Reflecting the widespread demand for a risk-free product, users came from 185 different countries. Surprisingly, gold was the top instrument with $1.4 billion in volume, outpacing bitcoin at $1.2 billion with precious metals accounting for roughly 35 percent of total pl
Phenom Positioned as Strategic Leader in Fosway 9-Grid™ for Talent Acquisition Sixth Consecutive Year2.6.2026 14:00:00 CEST | Press release
Recognition reflects sustained customer outcomes as enterprises move from AI experiments to production deployments Phenom, the leader in applied AI with an infrastructure built specifically to redesign work operations, has been positioned as a Strategic Leader in the 2026 Fosway 9-Grid™ for Talent Acquisition for the sixth year in a row. The positioning reinforces Phenom’s focus on sustained execution and customer impact at a moment when most enterprises remain stuck between AI ambition and AI that works. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602897994/en/ Phenom has been positioned as a Strategic Leader in the 2026 Fosway 9-Grid™ for Talent Acquisition for the sixth year in a row. The positioning reinforces Phenom’s focus on sustained execution and customer impact at a moment when most enterprises remain stuck between AI ambition and AI that works. The execution gap is well documented. Fosway’s recent AI Market
How Fit Analytics Innovation Reclaimed its Independence to Build the Future of AI Commerce2.6.2026 13:47:00 CEST | Press release
With today’s launch of the AI Shopping Assistant, Fit Analytics Innovation moves beyond the AI-hype-cycle to deliver the conversational guidance modern apparel shoppers crave. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602315868/en/ AI Shopping Assistant - Fit Analytics Innovation Two years ago, Fit Analytics Innovation did the unthinkable: they bought themselves back. Following a high-profile acquisition by Snap Inc., the management team recovered the award-winning Fit Finder and secured sixteen years of expertise and data insights. That bet on independence has culminated in the launch of the AI Shopping Assistant, the latest module available as part of their expanded product suite. Delivering Performance Over P.R. Unlike "overnight" AI startups rushing for market share, Fit Analytics has utilized its independence to prioritize depth over hype. The resulting AI Shopping Assistant is a native evolution of the company’
Kinaxis Introduces Forward Deployed Engineering to Help Enterprises Turn Decisions into Outcomes2.6.2026 13:01:00 CEST | Press release
New engineering-led engagement model helps organizations co-build AI-native operational solutions using the Maestro platform Kinaxis® Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today introduced Forward Deployed Engineering (FDE), a new engagement model designed to help enterprises operationalize AI and translate decisions into measurable business outcomes. FDE reflects the broader Kinaxis vision for operational orchestration, an approach that coordinates signals, decisions, actions and learnings across the business fast enough to change outcomes. The opening keynote at Kinexions, the company’s global customer conference, delivered by CEO Razat Gaurav will be livestreamed globally on June 2 @ 11:30 am EST via LinkedIn Live. This approach combines a unified data foundation with semantic intelligence that understands the relationships, dependencies, and trade-offs that shape enterprise operations. Together, these capabilities help organizations move beyond
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom